Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Asociación para Evitar la Ceguera en México

Overview

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Vogt Koyanagi Harada Disease Serpiginous Choroiditis Multifocal Choroiditis

Interventions

BevacizumabDRUG

Intravitreal Injection of BevacizumabPROCEDURE

Eligibility

Sex: ALLMin age: 25 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical Diagnose * Patient Consent * Chronic stage of inflammation Exclusion Criteria: * only eye * age lower than 30 yo. * Systemic condition

Locations (1)

Asociacion para Evitar la Ceguera en Mexico

Mexico City, Mexico City, Mexico

Outcomes

Primary Outcomes

Best corrected visual acuity

Retinal thickness by OCT

Leakage in Fluorescein angiogram

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.